Dexcom ONE is designed to continuously monitor glucose levels using a wearable sensor, and sends real-time readings wirelessly to a compatible smart device through the Dexcom ONE mobile app, which displays trend arrows that indicate the speed and direction of change in glucose levels
US-based continuous glucose monitoring (CGM) devices company DexCom has unveiled its plans to roll out the new Dexcom ONE system in the UK, starting from May this year.
Dexcom ONE is an easy-to-use real-time CGM (rt-CGM) system, with a wearable sensor and transmitter, that helps people control their diabetes.
It continuously monitors glucose levels and transmits real-time readings wirelessly to a compatible smart device through the Dexcom ONE mobile app.
Dexcom has specially designed the mobile app to display trend arrows that indicate the speed and direction of change in glucose levels, to support treatment decisions.
The app also provides a range of customisable alerts that help users side step the potentially dangerous high or low glucose events.
The company said that its new generation rt-CGM eliminates the need for painful fingerpricks, and provides an inexpensive option for people with diabetes in the UK.
Dexcom ONE is currently being reviewed by the NHS England, for possible addition to the drug tariffs across the UK regions.
Dexcom UK & Ireland, Benelux, France and Spain vice president Karen Baxter said: “The diabetes community represents a dynamic and inspiring group of individuals. It’s always been our priority to provide them with innovative and impactful technology.
“At Dexcom, we are constantly working to broaden access to CGM technologies that drive improved health outcomes. The upcoming launch of Dexcom ONE represents a significant step forward in diabetes management and inclusion on the drug tariff would ensure that more people benefit from this life changing technology.
“Should Dexcom ONE be added to the NHS drug tariff, Dexcom will implement an educational and support programme for people with diabetes and healthcare professionals to ensure the diabetes community can benefit as quickly as possible from reimbursement and wider availability of Dexcom CGM.”
The announcement follows the recent amendment of the National Institute for Health and Care Excellence (NICE) guidance on use of rtCGM by adults and children for the first time.
The new guidance from NICE recommends that people with Type 1 diabetes can choose their glucose sensors based on their individual preferences and the functionality of the devices.
In addition, the guidance also recommends that all children with Type 1 diabetes be offered rt-CGM, together with education for both them and their caregivers on the usage of the device.
The company will offer Dexcom ONE as part its range of diabetes products in the UK, including Dexcom G6 CGM system and the upcoming Dexcom G7 CGM system.
Dexcom ONE comes with the same sensing hardware as Dexcom G6 and can be used by people with Type 1 or Type 2 diabetes, who use insulin.